Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 7:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Contraception
Interventions
Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 29 Years · Female only
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
24
States / cities
Tucson, Arizona • La Mesa, California • San Diego, California + 8 more
Conditions
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
18
States / cities
Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Truclear on Patient Quality of Life

NCT02934789
Conditions
Heavy Menstrual Bleeding
Interventions
Hysteroscopic myomectomy with Truclear, Medical therapy
Procedure · Drug
Lead sponsor
All For Women Healthcare, Illinois
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

NCT02357368
Conditions
HIV, Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD), ParaGard® T 380A Intrauterine Copper Contraceptive
Drug · Device
Lead sponsor
Lisa Haddad
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia
Conditions
Contraception
Interventions
Paragard, Mirena
Device · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EC PK in Women With Normal and Obese BMI

NCT02689804
Conditions
Contraception
Interventions
LNG-EC, UPA-EC
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitrous Oxide for Pain Management of Intrauterine Device (IUD) Insertion

NCT02391714
Conditions
Contraception
Interventions
IUD insertion, Povidone-Iodine, Chlorhexidine, Oxygen, Nitrous oxide
Procedure · Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
12 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Contraception
Interventions
Levonorgestrel-releasing IUD (Mirena)
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions
Levonorgestrel IUS, Tranexamic Acid
Drug
Lead sponsor
Shannon K. Laughlin-Tommaso
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Michigan Contraceptive Access, Research, and Evaluation Study: Phase 1

NCT03673007
Conditions
Pregnancy
Interventions
Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019), Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
4,633 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
9
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Ferndale, Michigan + 6 more
Conditions
IUD, Contraceptive Implant, Contraception, Birth Control, Emergency Contraception
Interventions
Copper T-380 IUD, LNG IUD, Contraceptive implant Nexplanon, Depo-Provera
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
West Valley City, Utah
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial

NCT00653159
Conditions
Contraception
Interventions
Levonorgestrel-releasing intrauterine device (LNG-IUS), Copper T380A intrauterine device (CuT380A)
Device
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Ovulation in Obese Women

NCT06306131
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Acting Reversible Contraception

NCT01299116
Conditions
Contraception
Interventions
DMPA, oral contraceptives, Implanon®, ParaGard®, Mirena®
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
916 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 3 Interventional Results available

Mirena Extension Trial

NCT02985541
Conditions
Contraception
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
49
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

LNG-IUS at 2 Weeks Postpartum

NCT02121067
Conditions
Contraception, Malposition of Intrauterine Contraceptive Device
Interventions
Levonorgestrel Intrauterine System (LNG-IUS)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Not listed Not applicable Interventional

Stopping Heavy Periods Project

NCT02002260
Conditions
Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions
Levonorgestrel intrauterine system, Combined oral contraceptives
Device · Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Terminated No phase listed Observational Accepts healthy volunteers

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

NCT01750476
Conditions
Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions
Mirena, Oral contraception, Depo-Provera
Drug
Lead sponsor
Thomas Cherpes, DVM, MD
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Does Skyla Insertion Timing Impact Bleeding?

NCT03074903
Conditions
Vaginal Bleeding
Interventions
Intrauterine system
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Morristown, New Jersey • Newark, New Jersey
Conditions
Ewing Sarcoma
Interventions
allogeneic stem cell transplantation, Clyclophosphamide, Fludarabina, Busulfan, Melphalan
Biological · Drug
Lead sponsor
University of Louisville
Other
Eligibility
Up to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Gestational Diabetes, Glucose Intolerance, Type 2 Diabetes, Intrauterine Contraception
Interventions
Mirena (Levonorgestrel IUD), Paragard (Copper IUD ) or Tubal Ligation
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Postpartum Period
Interventions
IUD, Diary
Device · Other
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Springfield, Massachusetts